Evidence map›Paper›PMID 36777980›Full record

ArticleThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2023

Evaluating the Effect of Eicosapentaenoic Acid in Children With Atopic Dermatitis: A Randomized Triple-Blind Clinical Trial.

Bahador Mirrahimi, Mahsa Moazemi, Narges Eslami, Elham Jamshidi, Mahshad Mir, Rezvaneh Mohebbi, Hadi Esmaily

Abstract read
In one paragraph

Article in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bahador MirrahimiDepartment of Clinical Pharmacy (BM, HS), School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mahsa MoazemiStudent Research Committee (MM, EJ), School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Narges EslamiDepartment of Allergy and Clinical Immunology (NE), Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Elham JamshidiStudent Research Committee (MM, EJ), School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mahshad MirPharmaceutical Sciences Research Center (MM, RM), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Rezvaneh MohebbiPharmaceutical Sciences Research Center (MM, RM), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hadi EsmailyDepartment of Clinical Pharmacy (BM, HS), School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the effects of dietary eicosapentaenoic acid (EPA) in children with atopic dermatitis.

methodsForty-eight children with atopic dermatitis were randomly allocated to receive either 250 mg twice daily EPA (n = 24) or placebo (n = 24) for 4 weeks. The absolute improvement in the SCORing Atopic Dermatitis (SCORAD) index and the necessity to use topical corticosteroids was evaluated.

resultsBased on an intention-to-treat analysis, after 2 weeks the scores decreased to 30.50 ± 8.91 and 38.34 ± 10.52 in the EPA and placebo groups, respectively (p = 0.015). Per-protocol analysis showed a decrease in scores to 18.01 ± 10.63 in the EPA group and to 30.11 ± 9.58 in the placebo group (p = 0.001). After 2 weeks, corticosteroid was needed in 11 (50.0%) patients in the EPA group and 14 (58.3%) patients in the placebo group (p = 0.571), and after 4 weeks, it was needed in 7 (33.3%) patients in the EPA group and 14 (63.6%) patients in the placebo group, respectively (p = 0.047).

conclusionsOur results show significant favorable effects of EPA on the SCORAD scale and with regard to the necessity for corticosteroid readministration. Few adverse effects were reported in the 2 groups. We conclude that EPA supplementation is a well-tolerated and effective add-on strategy for reducing the severity of atopic dermatitis in children.

Indexed as

atopicdermatitisdietary supplementeczemaeicosapentaenoic acidpediatrics

Identifiers

PMID36777980
PMCPMC9901318

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.